Women now have another drug they can take to prevent breast cancer from returning after surgery to remove the tumor.
The federal Food and Drug Administration on Wednesday approved a new use for Femara, a medication already licensed for treating advanced &to=http://english.pravda.ru/science/19/94/377/15522_walkingcancer.html' target=_blank>breast cancer. It now can be given as initial therapy to women past menopause who have early breast cancer, the agency said.
In Thursday's New England Journal of Medicine, a study reports that Femara was more effective at preventing recurrences than the current gold standard, tamoxifen.
Femara and Arimidex, a similar drug already licensed for early breast cancer, are aromatase inhibitors, which block production of estrogen, a hormone that fuels the growth of most tumors that develop after menopause. Tamoxifen works differently, by blunting the ability of estrogen to enter cells.
The published study, reported earlier this year in Europe, estimated that 84 percent of women given Femara versus 81 percent of those on tamoxifen would be alive without any signs of cancer five years after starting treatment.
The estimates were based on roughly two years of information on relapses among the 8,000 women in the study, done by researchers in the United States, Europe and Australia.